Advertisement
Home Blog Page 3483
Three wearable devices -- a patch

Wearable Devices Aim to Monitor Seizure Activity in Epilepsy

0
Three different approaches in development
Children with allergic disease may face as much as a doubling of their risk of hypertension and hyperlipidemia -- even if they aren't overweight

Pediatric Allergic Disease May Up Cardiovascular Risk

0
Findings held even after adjustment for obesity
For young people with egg allergy

Live Attenuated Flu Shot Feasible for Children With Egg Allergy

0
LAIV linked to low risk of systemic allergic reactions in young people with egg allergy
For patients with sleep disordered breathing

Expiratory Snoring Predicts COPD in Sleep Disordered Breathing

0
Linear combination of mean oxygen saturation, expiratory breathing predicts FEV1
For patients with glaucoma

Prostaglandin Analogs Impact Circadian IOP-Related Patterns

0
Only prostaglandin analogs achieve reduction of positive IOP slope from awake/sitting-sleep/supine
Initial certifiers have a broader intended scope of practice than the actual scope of practice reported by current practitioners

Newly Certified Doctors Intend to Provide Broader Scope of Practice

0
Intended scope of practice is broader than actual scope of practice reported by current practitioners
For patients with lentigo maligna

Staged Surgical Excision Superior for Treatment of Lentigo Maligna

0
During mean follow-up of 60 months, recurrence seen in four patients out of cohort of 100
Guidelines have been formulated for arterial conduits for coronary artery bypass graft surgery

Guidelines Formulated for Arterial Conduits in CABG

0
Use of arterial grafts should be part of the heart team discussion for determining optimal surgical approach
Vonvendi has been approved by the U.S. Food and Drug Administration to treat adults with von Willebrand disease.

FDA Approves Vonvendi to Treat von Willebrand Disease

0
Approved for the as-needed treatment and control of bleeding episodes in adults
Kanuma (sebelipase alfa) has been approved by the U.S. Food and Drug Administration as the first treatment for LAL deficiency (Wolman disease or cholesteryl ester storage disease).

FDA Approves Kanuma for Lysosomal Acid Lipase Deficiency

0
For treatment of LAL deficiency, also known as Wolman disease or cholesteryl ester storage disease